HER2+ subgroup also had significantly higher TMB level and MATH score but comparable PD‐L1 expression level and MSI status when compared with HER2− subgroup, indicating that GC patients with HER2 amplifications may be one of the potential benefit populations. The gene discussed is CD274; the disease is gastric cancer.